Pharma Mar Gains Approval for Cancer Drug in Argentina

Pharma Mar SA ( (ES:PHM) ) has provided an update.

Pharma Mar S.A., along with its partner Adium Pharma S.A., has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC). This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, reinforcing Pharma Mar’s position in the oncology market and providing a new treatment option for a particularly aggressive form of lung cancer.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

Pharma Mar S.A. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology drugs. The company is known for its innovative treatments targeting various forms of cancer, with a significant market presence in both Europe and Latin America.

YTD Price Performance: -1.63%

Average Trading Volume: 59,625

Technical Sentiment Signal: Buy

Current Market Cap: €1.41B

For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.